A copy of the Cell Therapeutics, Inc.'s (the "Company") press release, entitled "FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA" is furnished and not filed pursuant to Item 7.01 as Exhibit 99.1 hereto. Such information shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

On September 5, 2009, the Company announced that the U.S. Food and Drug Administration has notified the Company that a Prescription Drug User Fee Act action date of April 23, 2010 under standard review has been established regarding the Company's New Drug Application for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma.

(d) Exhibits

Exhibit
Number     Description
 99.1      Press Release, dated September 5, 2009, entitled "FDA Sets Action Date of
           April 23, 2010 for Review of Pixantrone NDA"